In the News
Prana Reports Phase II Results for Reach2HD Clinical Trial
February 18, 2014: Prana Biotechnology has announced the results of its Reach2HD Phase 2 clinical trial investigating PBT2 as a treatment for Huntington disease. The double-blind, placebo-controlled study was conducted by the Huntington Study Group at research sites in the United States and Australia. The study enrolled 109 individuals with Huntington disease who were randomly assigned to receive daily doses of either PBT2 250mg, PBT2 100mg, or placebo for 26 weeks.
Creatine Supplement to Slow Huntington's Disease
February 12, 2014: The first clinical trial of a drug intended to delay the onset of symptoms of Huntington’s disease (HD) reveals that high-dose treatment with the nutritional supplement creatine was safe and well tolerated by most study participants. In addition, neuroimaging showed a treatment-associated slowing of regional brain atrophy, evidence that creatine might slow the progression of presymptomatic HD.
April 13, 2014: Team Hope is HDSA's signature grassroots fundraising campaign designed to provide hope and support for those touched by this devastating disease. Team Hope Walks are a way to showcase individuals who want to raise awareness in their local communities.
The GHPP Clinic is staffed by a multidisciplinary team of medical professionals who specialize in the diagnosis and treatment of persons affected with HD. The team includes neurologists, a psychiatrist, clinical nurse specialist, neuropsychologists, a social worker, center coordinator, and dietician. Clinic visits include complementary scheduling for physical therapy, occupational therapy, speech and swallowing evaluations, mobility equipment referrals, and other recurring services.
The HDCRC provides services that address issues relating to the care of someone with HD. Assistance may include: general information and referrals, providing education and educational materials, support groups, genetic counseling, placement issues, in-service trainings in care facilities upon request of family member or care facility.
The HDCRC assists individuals at-risk for inheriting HD, who have made a decision to be tested or are contemplating being tested for the HD gene mutation. Individuals are screened and counseled for issues such as: ability to cope with positive or negative results, relationships with family and friends, insurance planning, marriage and/or family planning, legal issues, career decisions, and support system.
The goals of our professional education program are to expose healthcare professionals, police officers, school counselors, social workers, and other community members to a multidisciplinary approach to the care and needs of HD patients, to broaden their perspective, and to make them aware of the problems in caring for patients with HD, which lie outside of their traditional fields. Consultation and educational opportunities are provided to community professionals caring for patients and families affected by HD.
The HDCRC is active in clinical HD research. Participants include those affected with HD, individuals at-risk for HD, family members or friends, and volunteer research subjects. Studies include clinical drug trials, observational trials, neuropsychological studies, and genetic research.
Please contact Andrew Herndon
at (858) 246-1254
to confirm clinical trial or study availability and/or to get further information about specific trials or studies.
See a list of current clinical trials.
Huntington's Disease Clinical Research Center
at the Shiley-Marcos ADRC
8950 Villa La Jolla Dr., Suite C129 (Building C)
La Jolla, CA 92037
Tel: (858) 246-1254
Fax: (858) 246-1283